Moderna's Market Cap Surpasses BioNTech by Over Three Times Amid Diverging Biotech Pipelines
As of early October 2026, Moderna (MRNA) has a market cap near $90 billion — over three times that of BioNTech SE (BNTX), which is valued at under $25 billion. This divergence stems from contrasting developments in their mRNA-based cancer vaccine pipelines. Moderna's stock surged more than 660% year-to-date following promising Phase 3 results for its personalized melanoma treatment, intismeran autogene, combined with Merck’s Keytruda (MRK). In contrast, BioNTech halted a Phase 2 trial of its colorectal cancer vaccine due to ineffectiveness and faces uncertainty from the planned departure of co-founders Uğur Şahin and Özlem Türeci. Valuation metrics also reflect this divide: Moderna trades at over 32 times sales, while BioNTech is valued at just under eight times. Despite its lower valuation, BioNTech has a stronger analyst outlook — with 11 of 15 analysts recommending it as a buy and an average price target suggesting about 30% upside. In contrast, only three out of 20 Moderna analysts recommend buying the stock, with an average price target nearly 52.5% below its current share price.
Topics: BioNTech Moderna mRNA cancer vaccines stock market cap comparison